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Abstract
The impact of recent changes in and discrepancies between the breakpoints for cephalosporins and other antimicrobials, as determined
by CLSI and European Committee on Antimicrobial Susceptibility Testing (EUCAST), was analysed in patients with bloodstream infec-
tions caused by extended-spectrum b-lactamase (ESBL) producing Escherichia coli in Spain, was analysed. We studied a cohort of 191
episodes of bloodstream infection caused by ESBL-producing E. coli in 13 Spanish hospitals; the susceptibility of isolates to different anti-
microbials was investigated by microdilution and interpreted according to recommendations established in 2009 and 2010 by CLSI, and
in 2011 by EUCAST. Overall, 58.6% and 14.7% of isolates were susceptible to ceftazidime, and 35.1% and 14.7% to cefepime using the
CLSI-2010 and EUCAST-2009/2011 recommendations, respectively (all isolates would have been considered resistant using the previous
guidelines). Discrepancies between the CLSI-2010 and the EUCAST-2011 recommendations were statistically signiﬁcant for other anti-
microbials only in the case of amikacin (98.4% versus 75.9% of susceptible isolates; p <0.01). The results varied depending on the ESBL
produced. No signiﬁcant differences were found in the percentage of patients classiﬁed as receiving appropriate therapy, following the
different recommendations. Four out of 11 patients treated with active cephalosporins according to CLSI-2010 guidelines died (all had
severe sepsis or shock); these cases would have been considered resistant according to EUCAST-2011. In conclusion, by using current
breakpoints, extended-spectrum cephalosporins would be regarded as active agents for treating a signiﬁcant proportion of patients with
bloodstream infections caused by ESBL-producing E. coli.
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Introduction
The breakpoints for classifying organisms as susceptible or
resistant to different antimicrobial agents, as determined by
the CLSI and European Committee on Antimicrobial Suscep-
tibility Testing (EUCAST), have an extraordinary inﬂuence on
the surveillance of antimicrobial resistance as well as on the
treatment of infections worldwide. Hence, it is important
to analyse the impact of discrepancies and changes in
breakpoints recommended by these organizations because
any change or discrepancy could be signiﬁcant for bacteria
producing speciﬁc mechanisms of resistance, such as
extended-spectrum b-lactamases (ESBLs), as the therapeutic
options for infections caused by these isolates are limited.
In 2010, the CLSI changed the susceptibility breakpoints
for the Enterobacteriaceae from £8 mg/L to £1 in the case
of cefotaxime, and from £8 mg/L to £4 in the case of ceftazi-
dime; in addition, the interpretation of the breakpoint was
to be reported as found, irrespective of whether there was
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ESBL production [1]. Previously, ESBL-producers should be
reported as resistant to cephalosporins, regardless of the
MIC [2]. A similar recommendation had previously been
launched by EUCAST in 2009 and maintained in 2011,
although breakpoints for cefotaxime, ceftazidime and cefe-
pime were established at £1 mg/L [3]. The breakpoints for
carbapenems, determined by the CLSI in June 2010, also
changed from £4 mg/L to £1 for imipenem or meropenem,
and from £2 mg/L to £0.25 for ertapenem [1,2]. The current
breakpoints ﬁxed by EUCAST are £2 for imipenem and
meropenem, and £0.5 for ertapenem [3]. Finally, there are
also differences in the breakpoints for piperacillin-tazobactam
between CLSI and EUCAST (£16 mg/L and £8, respectively),
ciproﬂoxacin (£1 and £0.5), gentamicin/tobramycin (£4 and
£2) and amikacin (£16 versus £8) [1,3]. The objective of this
study was to analyse the impact of recent changes to and
discrepancies between the CLSI and EUCAST breakpoints in
patients with bloodstream infections caused by ESBL-produc-
ing Escherichia coli.
Materials and Methods
All 191 isolates from two concurrent, multicentre, prospec-
tive cohorts of community-onset and nosocomial blood-
stream infections caused by ESBL-producing E. coli were
studied; the methodology, epidemiology, and clinical and
microbiological features of both cohorts have been previ-
ously published [4,5]. Brieﬂy, the study included all cases of
community-onset and nosocomial bloodstream infection
caused by ESBL-producing E. coli detected in 13 tertiary
Spanish hospitals belonging to the Spanish Network for
Research in Infectious Diseases (REIPI) between October
2004 and January 2006. Patients were prospectively followed
for 30 days after bloodstream infection. Demographics, pre-
disposing factors, source, clinical severity, antimicrobial ther-
apy and outcome were recorded. The ﬁrst blood isolate of
each case was sent to a reference laboratory (Servicio de
Microbiologı´a, Hospital Universitario Virgen Macarena, Sevilla)
where identiﬁcation to species level was conﬁrmed using the
API 20E system (bioMe´rieux, Lyon, France), and susceptibility
results, ESBL characterization (by PCR testing of bla genes,
and sequencing) and clonal typing of isolates (by using the
repetitive extragenic palindromic-PCR method) were per-
formed. Susceptibility testing was performed by microdilu-
tion, following CLSI and EUCAST recommendations [1,3];
data on cefotaxime, ceftazidime, cefepime, amoxicillin-
clavulanic acid, piperacillin-tazobactam, imipenem, meropenem,
ertapenem, ciproﬂoxacin, gentamicin, tobramycin and amika-
cin are shown. To further evaluate the clinical data, we also
used the dosing-dependent pharmacokinetic–pharmacody-
namic breakpoints proposed by Frei et al. [6]. The study was
approved by the local Ethics committees of the participating
hospitals.
The ESBLs produced by the isolates were previously
reported separately for community and nosocomial onset
bloodstream infections [4,5]; combined data were as follows
(seven isolates produced two ESBLs): CTX-M, 161 isolates
(84%), including 122 isolates producing the cephotaxime
CTX-M-9 group enzymes (97 CTX-M-14 and 25 CTX-M-9),
42 CTX-M-1 enzymes (23 CTX-M-15, 15 CTX-M-32, 3 cefo-
taxime-M-1, and 1 CTX-M-19); SHV, 33 isolates (17%),
including 30 isolates producing SHV-12 and 3 SHV-2a; and 1
producing a TEM ESBL enzyme (TEM-52). Also, clonal typing
of the isolates showed that 185 different repetitive extragen-
ic palindromic-PCR proﬁles were found among the 191 iso-
lates included.
For the purposes of this analysis, isolates were considered
susceptible, intermediate or resistant using the CLSI-2009
guidelines [2], the CLSI update in 2010 [1], and EUCAST-
2011 recommendations [3]. Percentages were compared
using the chi-square test or the Fisher’s exact test, as appro-
priate, and MICs using the Mann–Whitney U test.
Results
Antimicrobial susceptibility data for the 191 isolates accord-
ing to the CLSI-2009, CLSI-2010 and EUCAST-2011 recom-
mendations are shown in Table 1. Using the CLSI-2009
criteria, all isolates were classiﬁed as resistant to cefotaxime,
ceftazidime and cefepime irrespective of the MIC, because an
ESBL was produced. For cefotaxime, no isolate would con-
tinue to be regarded as susceptible using the CLSI-2011 and
EUCAST-2011 recommendations, although two isolates (1%)
producing a CTX-M-9 group enzyme and a CTX-M-1 group
enzyme, respectively, would be considered intermediate
(MIC = 2 mg/L). For ceftazidime and cefepime, the CLSI-
2010 guidelines classiﬁed isolates as susceptible more often
than the EUCAST-2011 recommendations; this is particularly
relevant for isolates producing an ESBL from the CTX-M-9
group, in the case of ceftazidime and cefepime (88.8% and
21.1% were susceptible according to CLSI-2010, compared
with 23.3% and 2.6% according to EUCAST-2011), and for
isolates producing an ESBL in the SHV group, in the case of
cefepime (89.7% susceptible according to CLSI-2010, against
65.5% according to EUCAST-2011).
With regard to carbapenems, all isolates were considered
susceptible to ertapenem using CLSI-2009 and EUCAST-
2011 recommendations; however, using the modiﬁed CLSI-
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2010 guidelines, 187 isolates (97.7%) would continue to be
considered susceptible to ertapenem, but four isolates would
be classiﬁed as intermediate (two produced a CTX-M-9
group enzyme, two produced a CTX-M-1 group enzyme).
All isolates were susceptible to imipenem and meropenem
for all three sets of recommendations.
CLSI breakpoints for amoxicillin-clavulanic acid, piperacil-
lin-tazobactam, ciproﬂoxacin and aminoglycosides did not
change in CLSI-2010 recommendations with respect to 2009.
There were no signiﬁcant differences of susceptibility to
ciproﬂoxacin and gentamicin between CLSI-2010 and
EUCAST-2011. The percentage of isolates susceptible to piper-
acillin-tazobactam, tobramycin and amikacin was somewhat
higher using CLSI-2010 criteria rather than EUCAST-2011
(p values for comparisons: 0.07, 0.07, and 0.06, respectively).
The MIC50 and MIC90 values of the antimicrobials studied,
by ESBL group, are shown in Table 1. Overall, MICs for iso-
lates producing enzymes from the CTX-M-9 group were
lower than for the CTX-M-1 group in the case of ceftazidime
(p <0.001), amoxicillin-clavulanic acid p 0.004), piperacillin-ta-
zobactam (p <0.001), ciproﬂoxacin (p <0.001), tobramycin
(p <0.001), and amikacin (p <0.001). There were no signiﬁ-
cant differences in the cases of cefotaxime, cefepime, ertape-
nem and gentamicin. In addition, the CTX-M-9 group
showed higher MICs against ceftazidime than the SHV group
(p <0.001), but a lower MIC against cefotaxime (p <0.001)
and cefepime (p <0.001). MIC distributions for cefotaxime,
ceftazidime, cefepime, piperacillin-tazobactam, amoxicillin-cla-
vulanic acid and ertapenem, by group of ESBL produced, are
shown in Fig. 1.
TABLE 1. Susceptibilities of extended-spectrum b-lactamase-producing Escherichia coli isolates to relevant antimicrobials, by
CLSI-2009, CLSI-2010 and EUCAST-2011 criteria, and by ESBL group produced. Data are expressed as number of susceptible
isolates (percentage in each row). All 191 isolates were included in the totals. For CTX-M-9, CTX-M-1, and SHV groups, only
isolates producing one ESBL were included (116, 38, and 29 isolates, respectively)
Antimicrobial Isolates
MIC50–MIC90
(mg/L) CLSI-2009 CLSI-2010
EUCAST-
2011
Cefotaxime Total 256–256 0 0 0
CTX-M-9 group 256–256 0 0 0
CTX-M-1 group 256–256 0 0 0
SHV group 32–256 0 0 0
Ceftazidime Total 2–8 0 112 (58.6)a 28 (14.7)d
CTX-M-9 group 2–8 0 103 (88.8)a 27 (23.3)d
CTX-M-1 group 32–128 0 8 (21.1)b 1 (2.6)e
SHV group 64–128 0 0 0
Cefepime Total 64–64 0 67 (35.1)a 28 (14.7)d
CTX-M-9 group 64–64 0 31 (26.7)a 3 (2.6)d
CTX-M-1 group 64–64 0 8 (21.1)b 4 (10.5)
SHV group 1–16 0 26 (89.7)a 19 (65.5)f
Amoxicillin/clavulanic acid Total 8–16 NC 118 (61.8) 118 (61.8)*
CTX-M-9 group 8–16 NC 41 (35.3) 41 (35.3)*
CTX-M-1 group 16–32 NC 23 (60.5) 23 (60.5)*
SHV group 8–16 NC 6 (20.7) 6 (20.7)*
Piperacillin/tazobactam Total 2–8 NC 175 (91.6) 164 (85.9)g
CTX-M-9 group 2–8 NC 110 (94.8) 108 (93.1)
CTX-M-1 group 8–32 NC 31 (81.6) 23 (60.5)h
SHV group 2–8 NC 27 (93.1) 27 (93.1)
Ertapenem Total 0.03–0.125 191 (100) 187 (97.9)c 191 (100)i
CTX-M-9 group 0.03–0.125 116 (100) 114 (98.3) 116 (100)
CTX-M-1 group 0.03–0.125 38 (100) 36 (94.7) 38 (100)
SHV group 0.015–0.125 29 (100) 29 (100) 29 (100)
Ciproﬂoxacin Total 4–32 NC 62 (32.5) 59 (30.9)
CTX-M-9 group 4–32 NC 40 (34.5) 38 (32.8)
CTX-M-1 group 64–128 NC 6 (15.8) 6 (15.8)
SHV group 4–32 NC 12 (41.4) 11 (37.9)
Gentamicin Total 1–32 NC 152 (79.6) 145 (75.9)
CTX-M-9 group 1–32 NC 96 (82.8) 89 (76.7)
CTX-M-1 group 2–128 NC 27 (71.1) 27 (71.1)
SHV group 1–64 NC 23 (79.3) 23 (79.3)
Tobramycin Total 1–4 NC 175 (91.6) 164 (85.9)j
CTX-M-9 group 1–4 NC 106 (91.4) 102 (87.9)
CTX-M-1 group 8–64 NC 18 (47.4) 17 (44.7)
SHV group 1–4 NC 27 (93.1) 24 (82.8)
Amikacin Total 4–8 NC 188 (98.4) 171 (75.9)d
CTX-M-9 group 4–8 NC 116 (100) 113 (97.4)
CTX-M-1 group 4–16 NC 35 (92.1) 23 (60.5)d
SHV group 4–8 NC 29 (100) 28 (96.6)
*Not resistant.
NC: no change in breakpoints in the 2010 version. The p values for comparison between CLSI-2010 and CLSI-2009 (chi-square except where speciﬁed).
a£0.001; b0.002 (Fisher’s test); c0.06(Fisher’s test). The p values for comparing CLSI-2010 and EUCAST-2011 (chi-square except where speciﬁed): d£0.001; e0.007; f0.02;
g0.07; h0.04; i0.06 (Fisher’s test); j0.07. Remaining comparisons >0.1.
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As regards clinical impact, 132 patients received empirical
monotherapy (35 with amoxicillin-clavulanic acid (18.3% of
the whole series), 23 with cefotaxime (12%), 21 with imipe-
nem or meropenem (10.9%), 17 with piperacillin-tazobactam
(9.8%), 13 with ciproﬂoxacin or levoﬂoxacin (6.8%), four
with cefepime (2%), one with ceftazidime or amikacin (0.5%),
and 17 with miscellaneous agents); 50 received combined
therapy (18 with a b-lactam plus an aminoglycoside (9.4%),
14 with a b-lactam plus a ﬂuoroquinolone (7.3%), and 18
with other combinations), and nine did not receive empirical
therapy. Empirical therapy would be considered appropriate
in 102 (53.4%) episodes by CLSI-2009 criteria, and in 106
(55.5%) by CLSI-2010 criteria (p 0.6). According to
EUCAST-2011, empirical therapy was appropriate in 97
patients (50.8%) (p value for comparison with CLSI-2010;
p 0.3). Taking only the 133 patients treated with antimicrobi-
als who showed some difference between CLSI-2010 and
EUCAST-2011 recommendations (ceftazidime, cefepime,
piperacillin-tazobactam, carbapenems, ciproﬂoxacin, and am-
inoglycosides), 80 and 71 patients, respectively, received
appropriate empirical therapy (60.2% versus 53.4%; p 0.2).
There was no difference in mortality for patients receiving
inappropriate empirical therapy according to CLSI-2010 or
EUCAST-2011 breakpoints (16/53 (30.2%) versus 18/62
(29%), respectively; p 0.8).
Fifteen patients had an isolate for which the MIC to the
empirically used antibiotic showed a classiﬁcation discrepancy
depending on whether the CLSI-2009, CLSI-2010 or
EUCAST-2011 recommendations were used. Data and char-
acteristics are summarized in Table 2. Six patients (40%) died
(ﬁve of these with severe sepsis or shock at presentation,
plus one other). Among the cephalosporins, 11 patients
received appropriate therapy according to CLSI-2010 recom-
mendations (none would be considered appropriate by
EUCAST-2011); four died (36.3%). As a reference, two out
of the 29 patients empirically treated with a carbapenem
died (9.5%); the p value for the comparison (Fisher test,
two-tailed) is 0.1; of note, none of the eight patients present-
ing with severe sepsis or shock treated with a carbapenem
died. If recently proposed pharmacokinetic–pharmacody-
namic breakpoints (which are dependent on the dosing regi-
men) are applied, the mortality rate in the patients treated
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FIG. 1. Distribution of isolates according to minimal inhibitory concentrations (MIC) of cefotaxime, ceftazidime, cefepime, piperacillin/tazobac-
tam, amoxicillin/clavulanic acid and ertapenem, and by extended-spectrum b-lactamase (ESBL) group produced. Black bars, CTX-M-9 group; grey
bars, CTX-M-1 group; white bars, SHV group. Only isolates producing one ESBL are included. The most frequent ESBL per group was: CTX-M-
14 in the CTX-M-9 group; CTX-M-15 in the CTX-M-1 group; SHV-12 in the SHV group. It should be noticed that the MIC scale differs for er-
tapenem.
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with a cephalosporin and infected with organisms showing a
MIC below or equal that pharmacokinetic–pharmacodynamic
breakpoint was 14.2% (one out of seven patients), compared
with 100% (four out of four) in those showing a higher MIC
(p 0.01 by Fisher test). Four patients were treated with
piperacillin-tazobactam, with an MIC of 16 mg/L (susceptible
according to CLSI-2010, non-susceptible for EUCAST-2011);
one died.
Discussion
Our results show that the CLSI-2010 recommendations for
breakpoints for extended-spectrum cephalosporins and their
interpretation have a signiﬁcant impact on whether an invasive
ESBL-producing E. coli is classiﬁed as susceptible to extended-
spectrum cephalosporins. Hence, 58% and 35% of isolates
would now be considered susceptible to ceftazidime and cefe-
pime, and none to cefotaxime. In a collection of 21 ESBL-pro-
ducing E. coli isolated from complicated intra-abdominal
infections in the USA, 38%, 52% and 48% were considered sus-
ceptible to cefotaxime, ceftazidime and cefepime, respectively
[7]; ﬁgures from the Asia-Paciﬁc region were 0%, 19%, and 5%,
respectively [8]. Our study shows that a change in breakpoint
varies in impact depending on the ESBL group produced, so
discrepancies between studies might simply be attributable to
differences in regional prevalence of the ESBL type.
The recommendation that interpretation should be
reported according to MIC regardless of ESBL production
has less impact using EUCAST-2011 breakpoints than CLSI-
2010, because the EUCAST-2011 breakpoints are lower for
ceftazidime and cefepime. So, only 14.7% of isolates in our
series would be considered susceptible to either ceftazidime
or cefepime with EUCAST-2011 recommendations. In a
multi-country European surveillance study for recently iso-
lated ESBL-producing E. coli in complicated intra-abdominal
infections, susceptibility to cefotaxime, ceftazidime and cefe-
pime was 2.3%, 7.5% and 8.7%, respectively [9], with subtle
differences depending on whether the infection source was
hospital or community-onset [10].
Just as the susceptibility proﬁles for the isolates varied
depending on which ESBL group was produced, so the
impact of the different breakpoints varied accordingly. This
was more evident in isolates producing CTX-M-9 group
enzymes (mostly CTX-M-14) in the case of ceftazidime, and
in isolates producing an SHV group ESBL (mostly SHV-12) in
the case of cefepime. Furthermore, discrepancies between
CLSI-2010 and EUCAST-2011 recommendations caused dif-
ferences that were almost signiﬁcant in the percentage of
isolates susceptible to piperacillin-tazobactam (particularlyT
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among CTX-M-1 group producers, which were more fre-
quently resistant using EUCAST-2011 breakpoints), tobra-
mycin and amikacin. No differences were found for
ciproﬂoxacin or gentamicin.
Overall, the MICs of most antimicrobials against iso-
lates producing an ESBL in the CTX-M-1 group (mainly
CTX-M-15) were the same as or higher than those for iso-
lates producing an ESBL in the CTX-M-9 or SHV groups.
Johnson et al. [11] also found that CTX-M-15-producing
E. coli isolated in the USA showed a higher resistance score
than those producing other ESBLs. This could be related to
the fact that mobile genetic elements harbouring blaCTX-M-15
genes frequently harbour other resistance genes too, such as
blaOXA-1 (which confers resistance to b-lactamase inhibitors)
or aac(6¢)-Ib-cr (which affects aminoglycosides and ﬂuoroqui-
nolones) in the ST 131 clonal group, which are associated
with the presence of chromosomal mutations affecting ﬂuor-
oquinolones [11–13]. So, the type of ESBL produced should
be considered when comparing the percentage of susceptible
isolates in studies from different areas or using different rec-
ommendations.
Differences in breakpoint may also have important clinical
implications. Although the use of extended-spectrum cepha-
losporins had been discouraged for some time regardless of
MIC [14], these antimicrobials would now be considered
appropriate by current CLSI and EUCAST recommendations
provided that the MIC is low enough, according to some
pharmacokinetic–pharmacodynamic data [15,16] and small
case series [17]. Based on those recommendations, our data
indicate that cephalosporins would be considered appropri-
ate in a signiﬁcant number of cases. However, there is still
controversy about the efﬁcacy of cephalosporins, even for
isolates with a very low MIC because of the marked inocu-
lum effect in vitro [18], and because the MIC could increase
as the result of b-lactamase hyperproduction [19] or porin
loss [20]. Whether these aspects are associated with an
increased risk of failure during cephalosporin therapy for
ESBL-producing isolates with a low MIC has not been ade-
quately studied. In our study, the number of patients treated
with a low-MIC cephalosporin was low, probably reﬂecting
adherence to previous recommendations. However, we think
it is important to report all such patients, so that cumulative
experience can be analysed in greater detail in the future.
We found a high mortality rate in patients with a blood-
stream infection caused by ESBL-producing E. coli and treated
with a cephalosporin which would be considered as suscepti-
ble to ceftazidime or cefepime according to present CLSI cri-
teria. Most deaths occurred in patients with a severe
presentation. The importance of the dosing regimen is to be
taken into account. Although the dosing regimens were cor-
rect according to the approved labels of the drugs except in
one patient, they might have been insufﬁcient for some of
these organisms with borderline MICs, as suggested by the
data considering the dose-dependent pharmacokinetic–phar-
macodynamic breakpoints [6]. Hence, even though the data
should be interpreted with prudence because the number of
cases is low, we would suggest caution in the use of cephalo-
sporins, at least in patients with a severe presentation or
with infections associated with a high bacterial load [21],
and, if cephalosporins are used for ESBL-producers, a dosing
regimen that maximizes the probability of attaining the phar-
macokinetic–pharmacodynamic target considering the MIC
should be prescribed. Our data did not enable us to analyse
the clinical impact of discrepancies between CLSI-2010 and
EUCAST-2011 for breakpoints of other antimicrobials.
In conclusion, extended-spectrum cephalosporins would
be considered active agents for treating a signiﬁcant propor-
tion of patients with bloodstream infections caused by ESBL-
producing E. coli using the present breakpoints launched by
EUCAST and, particularly, CLSI. The proportion of suscepti-
ble isolates varies by type of ESBL produced. More clinical
data are necessary to support the present EUCAST and CLSI
recommendations for cephalosporin susceptibility for ESBL-
producers in different types of infections, but at present, EU-
CAST breakpoints seem safer in terms of clinical application.
There are also some signiﬁcant discrepancies between CLSI
and EUCAST when applied to other antimicrobials, although
there are insufﬁcient clinical data to evaluate the impact of
such differences.
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